Bortezomib was originally made in 1995 at Myogenics
- Bortezomib was originally made in 1995 at Myogenics.
- Bortezomib is also FDA-approved for use in the treatment of multiple myeloma & mantle cell Lymphoma.
- Bortezomib is a dipeptide Boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma.
- Bortezomib has a role as an antineoplastic agent, a proteasome inhibitor, a protease inhibitor and
- • an antiprotozoal drug.
- •Proteasomes are in cells. They help to break down proteins that the cell doesn't need. Bortezomibb blocks the proteasomes so the proteins build up inside the cell. The cell then dies.
- A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells.
- •Bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.
